Harmony Biosciences Holdings, Inc. (HRMY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Harmony Biosciences possesses full pricing power thanks to its unique non-narcotic drug Wakix. Business stability relies on patent protection and the expansion of its neuro-drug pipeline. The EV/EBITDA valuation level allows for a comparison of the total enterprise value with its operating profit, where 5.94 describes the current status of the metric. Leadership in the wakefulness-promoting niche protects the company from dumping.
HRMY (Harmony Pharma): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Harmony Biosciences|HRMY - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Harmony Pharma|HRMY - Aggregate Debt Obligations|Debts to Book Capitalization Harmony Biosciences Holdings, Inc.|HRMY - Company Long-Term Debt|Company Short-Term Debts Harmony Biosciences|Quick Liquidity harmonybiosciences.com
- business earnings and investment ratios data:
HRMY - Company Net Income|Expected Profit Harmony Biosciences|HRMY - Business Payback Period|Forward P/E Multiple Harmony Biosciences Inc|HRMY - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Harmony Pharma|HRMY - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Harmony Biosciences|HRMY - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months harmonybiosciences.com|HRMY - Earnings per share growth this year|Earnings growth forecast for next year Harmony Biosciences
- revenue and sales details:
Summary company analysis:Harmony Biosciences HRMY
By outsourcing production, Harmony Biosciences (HRMY) minimizes capital expenditures to focus on R&D, making the EV/EBITDA valuation trend a key indicator of its business model's efficiency. The ratio of enterprise value to operating profit allows investors to determine the asset's degree of undervaluation by excluding the impact of taxes and depreciation, which is critical when analyzing capital-intensive biopharmaceutical companies.
Who Harmony Biosciences competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biohaven Ltd. BHVN|AMLX (Amylyx) - Company Value to Operating Income Before Depreciation Ratio|Trevi Therapeutics Inc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation PRAX (Praxis Precision Medicines)|AVXL: EV/EBITDA Multiple|CBLL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization prothena.com|Enterprise Value to EBITDA Ratio Alector (ALEC)|Enterprise Value to EBITDA Ratio ANNX (annexonbio.com)|OMER - Company Value to EBITDA|EV/EBITDA Multiple NGNE (Neurogene Inc)|EV/EBITDA Multiple AC Immune S.A. ACIU|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio NMRA|SCLX (Scilex Holding Company) - Enterprise Value to EBITDA Ratio|TVGN (Tevogen Bio Holdings) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACOG (Alpha Cognition Corp) - EV/EBITDA Multiple|Cognition Therapeutics, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|SAVA (Cassava) - Business Value to Operating Income Before Depreciation|Assertio Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)
